Wall Street Zen Upgrades Kiniksa Pharmaceuticals International (NASDAQ:KNSA) to Buy

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

A number of other equities analysts have also recently commented on KNSA. Wedbush reissued an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Finally, Citigroup began coverage on Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA traded down $0.46 during trading hours on Friday, reaching $27.95. The company's stock had a trading volume of 596,493 shares, compared to its average volume of 517,846. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -111.80 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 1-year low of $17.38 and a 1-year high of $30.69. The company's 50-day moving average is $25.46 and its two-hundred day moving average is $22.25.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. Kiniksa Pharmaceuticals International's quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) EPS. Equities analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity

In related news, insider Ross Moat sold 18,259 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the completion of the transaction, the insider now directly owns 9,415 shares in the company, valued at approximately $191,030.35. This represents a 65.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sanj K. Patel sold 2,872 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $27.03, for a total value of $77,630.16. Following the completion of the transaction, the chief executive officer now owns 96,674 shares of the company's stock, valued at $2,613,098.22. The trade was a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 432,442 shares of company stock worth $11,816,889 over the last ninety days. Corporate insiders own 53.48% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Braidwell LP grew its position in Kiniksa Pharmaceuticals International by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares during the period. Vanguard Group Inc. grew its position in Kiniksa Pharmaceuticals International by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock worth $74,606,000 after acquiring an additional 151,604 shares during the period. Acadian Asset Management LLC grew its position in Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after acquiring an additional 651,700 shares during the period. Millennium Management LLC grew its position in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after acquiring an additional 67,452 shares during the period. Finally, Nuveen Asset Management LLC grew its position in Kiniksa Pharmaceuticals International by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after acquiring an additional 54,361 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.